Dr. Siegel on Pomalidomide in Lenalidomide-Refractory Patients With Myeloma

David M. Siegel, MD, PhD
Published: Wednesday, Jan 09, 2019



David M. Siegel, MD, PhD, chief of myeloma, John Theurer Cancer Center, professor of medicine, Hackensack Meridian Health, discusses the feasibility of using pomalidomide (Pomalyst) to treat patients with myeloma who have become refractory to lenalidomide (Revlimid).

When treating patients with myeloma, there is a traditional belief that once they become refractory to a drug, oncologists need to completely change classes of drugs for the next line of therapy—for example, going from an immunomodulatory agent to a proteasome inhibitor. A study presented at the 2018 ASH Annual Meeting challenged this dogma by assessing the efficacy of pomalidomide in patients who progressed on a lenalidomide-based regimen.

The trial suggested there was no detriment in doing this, and Siegel says the next steps are taking these patients and treating them with the commonly used regimen comprised of pomalidomide, corticosteroids, and daratumumab (Darzalex). Siegel adds that although these are early data in patients who have progressed on 1 or 2 prior lines of treatment, this is still potentially practice-changing.
SELECTED
LANGUAGE


David M. Siegel, MD, PhD, chief of myeloma, John Theurer Cancer Center, professor of medicine, Hackensack Meridian Health, discusses the feasibility of using pomalidomide (Pomalyst) to treat patients with myeloma who have become refractory to lenalidomide (Revlimid).

When treating patients with myeloma, there is a traditional belief that once they become refractory to a drug, oncologists need to completely change classes of drugs for the next line of therapy—for example, going from an immunomodulatory agent to a proteasome inhibitor. A study presented at the 2018 ASH Annual Meeting challenged this dogma by assessing the efficacy of pomalidomide in patients who progressed on a lenalidomide-based regimen.

The trial suggested there was no detriment in doing this, and Siegel says the next steps are taking these patients and treating them with the commonly used regimen comprised of pomalidomide, corticosteroids, and daratumumab (Darzalex). Siegel adds that although these are early data in patients who have progressed on 1 or 2 prior lines of treatment, this is still potentially practice-changing.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x